Become Affiliate

PepFlow

Download

The Barrier Defender

LL-37

The only human cathelicidin antimicrobial peptide, central to innate immune defense, barrier biology, wound-response signaling, and inflammation research.

InflammationWound repairSkin barrier
TierD
EvidencePreliminary
SafetyLimited Data
FDA statusNot Approved
Topical 503AFlagged
Last reviewed October 25, 2026 45 citations How to read these labels

What is LL-37?

LL-37 is the active C-terminal peptide generated from human cathelicidin hCAP18. It is produced at epithelial and immune barriers and is widely reviewed as a multifunctional antimicrobial and immune-modulating peptide.[1][3]

The molecule matters because it sits at the interface of microbes, skin and mucosal barriers, neutrophils, epithelial cells, and inflammatory signaling. That makes it relevant to wound, infection, rosacea, sepsis-biomarker, vitamin D, and immune-defense literature.[2][4][6]

LL-37 is not the same as the full hCAP18 precursor. The name refers to the mature 37-amino-acid peptide generated from human cathelicidin, while cathelicidin or hCAP18 can describe the broader precursor system. That naming distinction matters when comparing biomarker studies, topical formulations, and peptide products.[1][4]

What LL-37 is investigated for

LL-37 evidence is grouped by practical use case and topical, injectable, vaginal, and intratracheal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Antimicrobial defense

Topical, Injectable

50%Emerging

LL-37 is central to antimicrobial-defense biology; therapeutic claims need route-specific human trials and should not be generalized to chronic systemic injection.[1][2]

Human evidence

Human evidence is strongest for endogenous cathelicidin measurement, vitamin-D-linked LL-37 biology, and limited route-specific trials rather than systemic injectable treatment protocols.[1][2]

Animal / mechanistic evidence

Reviews support LL-37 as the only human cathelicidin and a multifunctional antimicrobial peptide.[1][2]

Skin and barrier inflammation

Topical

45%Preliminary

Skin-inflammatory relevance is context dependent; barrier-immunity findings should not be generalized into cosmetic or systemic anti-inflammatory benefit.[8][4]

Human evidence

Human studies often involve biomarkers or related interventions such as vitamin D rather than direct LL-37 treatment.[8][4]

Animal / mechanistic evidence

LL-37 is involved in epithelial immunity and inflammatory signaling at barrier surfaces.[8][4]

Wound healing

Topical

42%Preliminary

Topical wound healing is a legitimate LL-37 research area, but it remains adjunctive and should not replace standard wound care or infection management.[5][21][23]

Human evidence

Topical LL-37 has been studied in hard-to-heal venous leg ulcers and diabetic foot ulcers, with published randomized trial signals and ongoing registry context.[5][21][23][40]

Animal / mechanistic evidence

Barrier and wound literature links LL-37 with epithelial repair signaling, keratinocyte activity, angiogenesis, and antimicrobial defense at injured surfaces.[2][4]

Gut barrier support

Topical

30%Limited

Gut-barrier support remains a barrier-immunity hypothesis, not a validated GI treatment.[3][4]

Human evidence

No controlled human trial establishes exogenous LL-37 as a treatment for gut-barrier dysfunction or intestinal-permeability outcomes.[3][4]

Animal / mechanistic evidence

Reviews describe LL-37 activity at epithelial barrier surfaces, including antimicrobial and immune-signaling roles relevant to mucosal defense.[3][4]

Evidence snapshot

40%

Human evidence

Preliminary

Published human literature is strongest as biomarker and disease-context evidence, with topical trial activity still early. It does not establish broad clinical efficacy for LL-37 products.[6][40]

48%

Animal / preclinical

Preliminary

Preclinical literature supports antimicrobial, immune, wound, and barrier-response biology across models. Those models do not settle route-specific treatment effects.[2][3]

68%

Mechanism support

Moderate

Cathelicidin biology gives LL-37 a well-established innate-immunity mechanism. The practical caveat is that inflammatory effects can shift by tissue, dose, and disease context.[1][4]

Forms & administration

LL-37 has topical wound preparations and separate injectable research presentations. Vaginal and intratracheal formulations remain experimental, with animal-only evidence. Each route requires its own preparation and amount; direct airway delivery is distinct from nebulization and does not establish a human inhaled product.[40][4][36][42][43][44]

TopicalInjectableVaginalIntratracheal

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 500 mcg-1.6 mg per dose. Topical amounts depend on the product.[4][36]

Frequency

Injectable protocols usually use 1-2 doses daily. Topical schedules follow the wound-care plan.[40]

Timing Considerations

Use injections in the morning or evening. Apply topical products during dressing changes.[40]

Cycle Length

Injectable cycles commonly run 2-4 weeks.[40]

What to expect

First week

Topical wound or skin use may first show changes in redness, drainage, pain, surface irritation, or barrier comfort.[40]

Weeks 2-4

Wound size, barrier comfort, flare frequency, and pain are the clearest short-course patterns for topical use; injectable immune-support expectations remain much less concrete.[40][4]

After stopping

Barrier comfort and wound trajectory may hold, fade, or return toward baseline depending on wound care and other skin-care changes.[40]

Safety profile

Topical LL-37 safety centers on local irritation and wound-care context. Injectable or systemic exposure is a different risk category, with added immune-activation, sterility, product-quality, and unknown exposure concerns.[40][36][39]

Common side effects

  • Local irritation[40]

Cautions

  • Active infection or complex wounds[40]
  • Immune activation uncertainty[4]
  • Injectable product quality[38][39]

What we don't know

Injectable LL-37 lacks a mature human pharmacokinetic and long-term systemic safety base.[36]

Who LL-37 is not for

Route-specific avoid and medical-review notes:

  • Pregnancy or breastfeeding

    Avoid exogenous LL-37 because route-specific reproductive safety is not established.[36]

  • Untreated infected or complex wounds

    Medical wound care should come first; topical peptide use should not delay evaluation.[40]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Immunosuppressive therapy

    Immunosuppressive therapy could change infection and inflammation context for topical or injectable LL-37; this is a theoretical route-specific immune caution.[2]

How it works

LL-37 is the active human cathelicidin peptide at barrier surfaces. It can damage microbes directly, but its broader role is signaling: recruiting immune cells, changing inflammatory tone, and influencing epithelial and wound-response behavior.[1][2][3]

That dual action is why route matters. Topical LL-37 logic is tied to local skin or wound exposure, while injectable or systemic use would expose immune-active pathways more broadly. Endogenous host-defense biology should not be read as proof that added LL-37 improves immunity or healing in people.[4][22][40]

Research gaps & open questions

What the current literature has not yet settled about LL-37:

01

Completed human trials need to show whether topical LL-37 actually improves wound closure, infection control, pain, or scarring—not only laboratory measures.[40]

02

Human studies need to show how injectable LL-37 is absorbed and cleared, how strongly it activates the immune system, and whether repeated exposure is safe.[36][4]

03

Trials need to separate conditions where LL-37 may help fight infection from conditions where it could worsen harmful inflammation.[2]

Common questions

What is LL-37?

LL-37 is the active human cathelicidin antimicrobial peptide, a barrier-defense signal involved in microbial responses, inflammation, and wound biology.[1][2]

Is LL-37 an antibiotic?

No. LL-37 has antimicrobial peptide biology, but topical or injectable LL-37 is not a substitute for antibiotics, infection care, or wound management.[3][40]

Is LL-37 FDA-approved?

No. LL-37 has no FDA-approved topical or injectable drug use as of 2026-06-21; topical trials and research-market products do not create market authorization.[36][39]

Myths & misconceptions

Myth

Because LL-37 is natural, exogenous LL-37 is automatically safe.

Reality

Endogenous barrier biology does not establish safety for concentrated topical products or systemic injections.[4][36]

Myth

LL-37 is a simple immune booster.

Reality

LL-37 is immune-active and context-dependent, which is different from a predictable immune boost.[2]

History & discovery

LL-37's history starts in human cathelicidin biology: hCAP18 processing produces a 37-amino-acid peptide that became a model for barrier defense, immune signaling, and wound biology.[1][2]

Reviews established LL-37 as the mature active peptide from hCAP18, the only human cathelicidin, distinguishing it from conventional antibiotics or generic antimicrobial products.[1][3]

Research expanded from direct antimicrobial activity into chemotaxis, epithelial activation, angiogenesis, inflammation control, and other host-defense functions.[2][3]

Topical LL-37 cream moved into diabetic-foot-ulcer testing, a route-specific therapeutic question separate from injectable compounding discussions.[40]

Published research45 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Bring consistency to your well-being routine.

Use PepFlow to record your LL-37 protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00